Advancements in Midline Catheter Technology by Access Vascular
Access Vascular’s Breakthrough in Catheter Technology
Access Vascular, Inc., involved in innovative vascular access solutions, has recently shared compelling findings regarding its midline catheter technology. These findings were introduced at a prominent annual scientific meeting of the Association for Vascular Access. Through rigorous evaluations, the company demonstrated a marked reduction in complications associated with its HydroMID™ catheter compared to traditional options.
Evaluating Complications with Traditional versus Advanced Catheters
Comparison studies highlighted the significant benefits of the HydroMID catheter, particularly its reduced complication rates. The device exhibited a complication rate of just 5%, which starkly contrasts with the 25% rate seen with conventional chlorhexidine gluconate-coated catheters. Interestingly, the average dwell time for HydroMID was longer at 10.5 days versus 8.9 days, yet it maintained an impressive 95% completion of therapy compared to less than 80% for its counterpart. These outcomes indicate a substantial stride in ensuring patient safety and treatment efficacy.
Study Insights from Healthcare Professionals
Stevie Gore, an RN participating in the study from Benefis Health System, elaborated on the benefits experienced post-switching to HydroMID. The study aimed to address the growing concerns around midline catheter complications, such as pain, swelling, and catheter-related thrombosis. Gore expressed, 'Our patients have reaped the rewards of lower incidents of pain, swelling, and other complications since adopting the HydroMID catheter.'
HydroMID Catheter's Unique Benefits and Technology
The innovative HydroMID catheter is designed using Access Vascular's proprietary MIMIX™ hydrophilic biomaterial technology, which imitates the body's natural chemistry. Research has indicated that the company’s products can reduce complications by as much as sixfold compared to standard catheters. The in vitro studies revealed a remarkable 99.99% reduction in bacterial adhesion, underscoring the significant role this technology plays in improving clinical outcomes.
About Access Vascular: A Closer Look
Founded with the mission to combat primary complications arising from intravenous therapy, Access Vascular focuses on reducing instances of infection and thrombosis that patients commonly face. This commitment to patient care drives the design and manufacture of advanced intravenous catheters from hydrophilic materials aimed to counteract the body's foreign response to traditional devices. Their FDA-cleared products, HydroPICC® and HydroMID®, exemplify excellence in vascular access technology.
Emphasis on Future Developments
Furthermore, as healthcare continues to evolve, Access Vascular remains at the forefront of innovation in vascular access solutions. The potential implications of their findings emphasize the importance of improving patient care while mitigating complications during intravenous therapy. Investing in continued research and development could yield even more effective solutions for health providers and their patients.
Patient Safety: A Top Priority
Access Vascular’s focus on patient safety is paramount, as their advanced technologies aim to provide healthier interactions for patients requiring vascular access. The commitment to lowering failure and complication rates aligns with global healthcare objectives to ensure that patient experiences are safe and effective.
Frequently Asked Questions
What is the HydroMID catheter?
The HydroMID catheter is an advanced vascular access device made from a hydrophilic biomaterial that reduces complications compared to standard catheters.
What were the study findings?
The study found that the HydroMID catheter had a complication rate of 5%, significantly lower than the 25% rate for traditional catheters.
How does Access Vascular ensure safety?
Access Vascular designs its products to mimic the body’s natural chemistry, aiming to reduce foreign body responses and associated complications.
What is MIMIX™ technology?
MIMIX™ technology refers to the proprietary biomaterial developed by Access Vascular, which is engineered to minimize complications during intravenous therapy.
What are the core products offered by Access Vascular?
Access Vascular offers the HydroPICC® and HydroMID® catheters, both designed to enhance patient safety during vascular access procedures.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Barclays Highlights Potential Earnings Challenges for Big Tech
- Sonatype Gains Esteemed AWS Security Competency Recognition
- Revolutionizing DeFi: Glue Network Enhances Access with Banxa
- RIFM to Host 3rd Annual Science Symposium Focusing on Safety
- Treasury Wine Estates Teams Up with Hello Sunshine for New Wines
- Innovative Startups Join Forces in New WealthTech Accelerator
- Global Pet Supplement Market to Exceed $1 Billion by 2035
- Metallurgical Coal Market Forecast: Surplus Ahead by 2025
- Maria Lensing Steps Up as CTO of Sorenson to Drive Innovation
- AE Industrial Partners Welcomes Leonard Dollaga as Managing Director
Recent Articles
- Wendy Kei Receives Visionary Award for Leadership and Impact
- Sandy Spring Bancorp to Host Q3 Earnings Webcast Soon
- Revolutionizing Staffing Compliance: Onboarded's New Solution
- Climb Channel Solutions Enters LATAM Market with Bluebeam
- OXIO Appoints Telecom Veteran Angela Lim as Chief Growth Officer
- Navigating Social Security Benefits: Key Considerations
- VedaBio Welcomes Randy Rasmussen to Board of Directors
- Lifecore Biomedical Partners with Lindy Biosciences for New Technology
- Exploring Affordable Dividend Stocks for Passive Income
- JOYA Introduces Innovative Skin Health Platform for Employees
- Willis Lease Finance Corporation Secures Series A Investment
- Empowering Women Through Breast Health Awareness Initiatives
- Colliers Inks Extended Deal with CEO Jay S. Hennick
- Novocure's Upcoming Q3 2024 Financial Announcement Details
- Chevron Corporation's Upcoming Earnings Call Details and Insights
- MAG Aerospace and Zapata AI Unite for Innovative ISR Solutions
- Fluor Corporation's Upcoming Earnings Conference Call Details
- Y-mAbs Highlights Key Investor Conferences This October
- Exciting Insights Ahead: Herbalife's Q3 2024 Results Preview
- QuantaSing's New Special Dividend Set to Reward Shareholders
- Laser Photonics Partners with Hemlock Semiconductor for Innovation
- Codexis Partners with Alphazyme to Enhance Enzyme Solutions
- Emcore Corporation Evaluates Purchase Proposal from Mobix Labs
- Sandy Spring Bancorp to Host Earnings Call for Q3 Results
- Health Assurance Foundation Teams Up to Enhance Healthcare Access
- Calian and Walmart Canada Team Up for Enhanced Pharmacy Services
- IBM's Nickle LaMoreaux Earns Prestigious HR Executive Title
- Innovative Collaboration Between Japan Tobacco and D-Wave on Drug Discovery
- OPTEL and Worximity Collaborate to Enhance Operational Efficiency
- Adeia and VIZIO Collaborate in a Strategic IP License Renewal
- Chemomab Therapeutics to Engage Investors in October Conferences
- STP Launches Innovative BluePrint Platform for Investment Firms
- Jennifer Cable Joins J2 Ventures Advisory Board to Drive Innovation
- Marex Expands Global Reach with Dropet Biofuels Acquisition
- Simply Good Foods Prepares to Share Financial Results Soon
- Pebblebrook Hotel Trust Unveils 2024 Sustainability Achievements
- Legal-Bay Launches Informative Q&A Webpage for Plaintiffs
- Foghorn Therapeutics: Transforming Oncology at Upcoming Summit
- InspiroGene by McKesson: Revolutionizing Cell and Gene Therapies
- Valens Semiconductor Launches Advanced VA7000 and VS6320 Chipsets
- Canadian Solar's e-STORAGE Revolutionizes Energy in Chile
- Intertek Launches Innovative Global Compliance Service
- InMode Restructures Leadership for Strategic Growth Initiatives
- Revolutionizing Travel Safety: BOXX Insurance's Cyber Solution
- Dentalcorp: Celebrating Success as a Top Growing Company in Canada
- BOXX Insurance and World Travel Protection Launch Cyber Assist
- RedHill's Talicia® Secures Ongoing Access for Millions in California
- Meketa Investment Group Achieves Milestone Growth with New Team
- Sealed Air Welcomes Anthony Allott to Board of Directors
- Willis Lease Finance Corporation’s Major Preferred Stock Deal